• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Waters Corporation (NYSE: WAT) Reports First Quarter 2024 Financial Results

    5/7/24 6:50:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $WAT alert in real time by email

    Highlights

    • Sales of $637 million at the high-end of guidance, declined 7% as reported and 9% in organic constant currency
    • GAAP EPS of $1.72; earnings well above guidance, with non-GAAP EPS of $2.21
    • Operational excellence drove gross margin expansion of 40 basis points and adjusted operating margin expansion of 20 basis points
    • Strong operating cash flow generation at $263 million; free cash flow of $234 million was 37% of sales
    • Full-year guidance maintained at -0.5% to +1.5% organic constant currency sales growth and non-GAAP EPS of $11.75 to $12.05

    First Quarter 2024

    MILFORD, Mass., May 7, 2024 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced its financial results for the first quarter of 2024.

    Sales for the first quarter of 2024 were $637 million, a decrease of 7% as reported, compared to sales of $685 million for the first quarter of 2023. Currency translation decreased sales by 1%, while the impact of acquisitions increased sales by 3%.

    On a GAAP basis, diluted earnings per share (EPS) for the first quarter of 2024 was $1.72, compared to $2.38 for the first quarter of 2023. On a non-GAAP basis, EPS was $2.21, compared to $2.49 for the first quarter of 2023. This includes a headwind of approximately 4% due to unfavorable foreign exchange.

    "Our first quarter revenues were at the high end of our guidance as our team continues to execute well," said Dr. Udit Batra, President & CEO, Waters Corporation. "The margin expansion we delivered reflects the strength of our operational performance, especially when considering current volume and foreign exchange headwinds."

    Dr. Batra continued, "With our steady stream of innovative new products and focus on higher growth areas, we are well-positioned in our attractive end-markets."

    Other Highlights

    During the first quarter of 2024, sales into the pharmaceutical market decreased 3% as reported and 6% in organic constant currency, sales into the industrial market decreased 7% as reported and in organic constant currency, and sales into the academic and government market decreased 25% as reported and 30% in organic constant currency.

    During the quarter, instrument system sales decreased 20% as reported and 25% in organic constant currency, while recurring revenues, which represent the combination of service and precision chemistries, increased 3% as reported and in organic constant currency.

    Geographically, sales in Asia during the quarter decreased 18% as reported and 16% in organic constant currency. Sales in the Americas decreased 2% as reported and 8% in organic constant currency. Sales in Europe increased 2% as reported and decreased 3% in organic constant currency.

    Unless otherwise noted, sales growth and decline percentages are presented on an as-reported basis. A description and reconciliation of GAAP to non-GAAP results appear in the tables below and can be found on the Company's website www.waters.com in the Investor Relations section.

    Full-Year and Second Quarter 2024 Financial Guidance

    Full-Year 2024 Financial Guidance

    The Company continues to expect full-year 2024 organic constant currency sales growth to be in the range of -0.5% to +1.5%. Currency translation is expected to decrease full-year sales growth by slightly less than 1%. M&A contribution from the Wyatt transaction covering the first four-and-a-half months of the year is expected to increase full-year reported sales growth by slightly over 1%. The resulting full-year 2024 reported sales growth is expected in the range of 0.0% to +2.0%.

    The Company expects full-year 2024 non-GAAP EPS to be in the range of $11.75 to $12.05, which includes an estimated headwind of approximately 2% due to unfavorable foreign exchange.

    Please refer to the tables below for a reconciliation of the projected GAAP to non-GAAP financial outlook for the full year.

    Second Quarter 2024 Financial Guidance

    The Company expects second quarter 2024 organic constant currency sales growth to be in the range of -6.0% to -4.0%. Currency translation is expected to decrease second quarter sales growth by approximately 2%. M&A contribution from the Wyatt transaction covering the first-month-and-a-half of the quarter is expected to increase second quarter reported sales growth by approximately 1.5%. The resulting second quarter 2024 reported sales growth is expected in the range of -6.5% to -4.5%.

    The Company expects second quarter 2024 non-GAAP EPS to be in the range of $2.50 to $2.60, which includes an estimated headwind of approximately 4% due to unfavorable foreign exchange.

    Please refer to the tables below for a reconciliation of the projected GAAP to non-GAAP financial outlook for the second quarter.

    Conference Call Details

    Waters Corporation will webcast its first quarter 2024 financial results conference call today, May 7, 2024, at 8:00 a.m. Eastern Time. To listen to the call and see the accompanying slide presentation, please visit www.waters.com, select "Investor Relations" under the "About Waters" section, navigate to "Events & Presentations," and click on the "Webcast." A replay will be available through June 4, 2024 on the same website by webcast and also by phone at (800) 839-9317.

    About Waters Corporation

    Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. With approximately 7,700 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries. For more information, visit www.waters.com.

    Non-GAAP Financial Measures

    This press release contains financial measures, such as organic constant currency growth rates, adjusted operating income, adjusted net income, adjusted earnings per diluted share and free cash flow, among others, which are considered "non-GAAP" financial measures under applicable U.S. Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP). The Company's definitions of these non-GAAP measures may differ from similarly titled measures used by others. The non-GAAP financial measures used in this press release adjust for specified items that can be highly variable or difficult to predict. The Company generally uses these non-GAAP financial measures to facilitate management's financial and operational decision-making, including evaluation of the Company's historical operating results, comparison to competitors' operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company's business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management strongly encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this release.

    Cautionary Statement

    This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "feels", "believes", "anticipates", "plans", "expects", "intends", "suggests", "appears", "estimates", "projects" and similar expressions, whether in the negative or affirmative, are intended to identify forward-looking statements. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements within this release for a variety of reasons, including and without limitation, risks related to, and expectations or ability to realize commercial success of the Wyatt transaction; the impact of this transaction on the Company's business, anticipated progress on Waters' research programs, development of new analytical instruments and associated software or consumables, manufacturing development and capabilities; the increased indebtedness of the Company as a result of the Wyatt transaction, the repayment of which could impact the Company's future results, market prospects for its products and sales and earnings guidance; foreign currency exchange rate fluctuations potentially affecting translation of the Company's future non-U.S. operating results, particularly when a foreign currency weakens against the U.S. dollar; current global economic, sovereign and political conditions and uncertainties, including the effect of new or proposed tariff or trade regulations as well as other new or changed domestic and foreign laws, regulations and policies; changes in inflation and interest rates; the impacts and costs of war, in particular as a result of the ongoing conflicts between Russia and Ukraine and in the Middle East, and the possibility of further escalation resulting in new geopolitical and regulatory instability; the Chinese government's ongoing tightening of restrictions on procurement by government-funded customers; the Company's ability to access capital, maintain liquidity and service the Company's debt in volatile market conditions; risks related to the effects of any pandemic on our business, financial condition, results of operations and prospects; changes in timing and demand for the Company's products among the Company's customers and various market sectors, particularly as a result of fluctuations in their expenditures or ability to obtain funding; the ability to realize the expected benefits related to the Company's various cost-saving initiatives, including workforce reductions and organizational restructurings; the introduction of competing products by other companies and loss of market share, as well as pressures on prices from competitors and/or customers; changes in the competitive landscape as a result of changes in ownership, mergers and continued consolidation among the Company's competitors; regulatory, economic and competitive obstacles to new product introductions; lack of acceptance of new products and inability to grow organically through innovation; rapidly changing technology and product obsolescence; risks associated with previous or future acquisitions, strategic investments, joint ventures and divestitures, including risks associated with achieving the anticipated financial results and operational synergies; contingent purchase price payments and expansion of our business into new or developing markets; risks associated with unexpected disruptions in operations; failure to adequately protect the Company's intellectual property, infringement of intellectual property rights of third parties and inability to obtain licenses on commercially reasonable terms; the Company's ability to acquire adequate sources of supply and its reliance on outside contractors for certain components and modules, as well as disruptions to its supply chain; risks associated with third-party sales intermediaries and resellers; the impact and costs of changes in statutory or contractual tax rates in jurisdictions in which the Company operates as well as shifts in taxable income among jurisdictions with different effective tax rates, the outcome of ongoing and future tax examinations and changes in legislation affecting the Company's effective tax rate; the Company's ability to attract and retain qualified employees and management personnel; risks associated with cybersecurity and technology, including attempts by third parties to defeat the security measures of the Company and its third-party partners; increased regulatory burdens as the Company's business evolves, especially with respect to the U.S. Food and Drug Administration and U.S. Environmental Protection Agency, among others, and in connection with government contracts; regulatory, environmental and logistical obstacles affecting the distribution of the Company's products, completion of purchase order documentation and the ability of customers to obtain letters of credit or other financing alternatives; risks associated with litigation and other legal and regulatory proceedings; and the impact and costs incurred from changes in accounting principles and practices. Such factors and others are discussed more fully in the sections entitled "Forward-Looking Statements" and "Risk Factors" of the Company's annual report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission ("SEC"), which discussions are incorporated by reference in this release, as updated by the Company's future filings with the SEC. The forward-looking statements included in this release represent the Company's estimates or views as of the date of this release and should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this release. Except as required by law, the Company does not assume any obligation to update any forward-looking statements.

    Waters Corporation and Subsidiaries

    Consolidated Statements of Operations

    (In thousands, except per share data)

    (Unaudited)















    Three Months Ended



    March 30, 2024



    April 1, 2023









    Net sales

    $               636,839



    $               684,674









    Costs and operating expenses:







    Cost of sales

    261,786



    284,380

    Selling and administrative expenses

    174,536



    181,956

    Research and development expenses

    44,595



    42,691

    Purchased intangibles amortization

    11,834



    1,479

    Litigation provision

    10,242



    -









    Operating income

    133,846



    174,168









    Other income, net

    2,259



    1,388

    Interest expense, net

    (21,249)



    (10,383)









    Income from operations before income taxes

    114,856



    165,173









    Provision for income taxes

    12,660



    24,250









    Net income

    $               102,196



    $               140,923

















    Net income per basic common share

    $                     1.73



    $                     2.39









    Weighted-average number of basic common shares

    59,232



    59,023

















    Net income per diluted common share

    $                     1.72



    $                     2.38









    Weighted-average number of diluted common shares and equivalents

    59,431



    59,317









     





































    Waters Corporation and Subsidiaries

    Reconciliation of GAAP to Adjusted Non-GAAP

    Net Sales by Operating Segments, Products & Services, Geography and Markets

    Three Months Ended March 30, 2024 and April 1, 2023

    (In thousands)





































    Organic



































    Constant











    Three Months Ended



    Percent



    Impact of



    Impact of



    Currency











    March 30, 2024



    April 1, 2023



    Change



    Currency



    Acquisitions



    Growth Rate (a)





































    NET SALES - OPERATING SEGMENTS





























































    Waters







    $

    561,899



    $

    602,075



    (7 %)



    (1 %)



    4 %



    (10 %)

    TA











    74,940





    82,599



    (9 %)



    (1 %)



    0 %



    (9 %)





































    Total







    $

    636,839



    $

    684,674



    (7 %)



    (1 %)



    3 %



    (9 %)









































































    NET SALES - PRODUCTS & SERVICES

































































    Instruments





    $

    241,944



    $

    302,942



    (20 %)



    0 %



    5 %



    (25 %)





































    Service









    260,688





    248,217



    5 %



    (1 %)



    2 %



    4 %

    Chemistry







    134,207





    133,515



    1 %



    (1 %)



    0 %



    2 %

    Total Recurring







    394,895





    381,732



    3 %



    (1 %)



    2 %



    3 %





































    Total







    $

    636,839



    $

    684,674



    (7 %)



    (1 %)



    3 %



    (9 %)









































































    NET SALES - GEOGRAPHY

































































    Asia









    $

    207,559



    $

    253,081



    (18 %)



    (3 %)



    1 %



    (16 %)

    Americas









    241,171





    246,421



    (2 %)



    0 %



    6 %



    (8 %)

    Europe









    188,109





    185,172



    2 %



    2 %



    2 %



    (3 %)





































    Total







    $

    636,839



    $

    684,674



    (7 %)



    (1 %)



    3 %



    (9 %)









































































    NET SALES - MARKETS



































































    Pharmaceutical





    $

    374,207



    $

    384,898



    (3 %)



    (1 %)



    4 %



    (6 %)

    Industrial









    195,334





    209,650



    (7 %)



    (1 %)



    1 %



    (7 %)

    Academic & Government







    67,298





    90,126



    (25 %)



    2 %



    3 %



    (30 %)





































    Total







    $

    636,839



    $

    684,674



    (7 %)



    (1 %)



    3 %



    (9 %)











































































































    (a)



    The Company believes that referring to comparable organic constant currency growth rates is a useful way to evaluate the underlying performance of Waters Corporation's net sales. Organic constant currency growth, a non-GAAP financial measure, measures the change in net sales between current and prior year periods, excluding the impact of foreign currency exchange rates during the current period and excluding the impact of acquisitions made within twelve months of the acquisition close date. See description of non-GAAP financial measures contained in this release.

     

    Waters Corporation and Subsidiaries

    Reconciliation of GAAP to Adjusted Non-GAAP Financials

    Three Months Ended March 30, 2024 and April 1, 2023

    (In thousands, except per share data)





































































































    Income from



























































    Operations





























    Selling &





    Research &











    Operating











    before





    Provision for











    Diluted











    Administrative





    Development





    Operating





    Income





    Other





    Income





    Income





    Net





    Earnings











    Expenses(a)





    Expenses





    Income





    Percentage





    Income





    Taxes





    Taxes





    Income





    per Share

    Three Months Ended March 30, 2024























































    GAAP



    $

    196,612



    $

    44,595



    $

    133,846





    21.0 %



    $

    2,259



    $

    114,856



    $

    12,660



    $

    102,196



    $

    1.72

    Adjustments:

























































    Purchased intangibles amortization (b)





    (11,834)





    -





    11,834





    1.9 %





    -





    11,834





    2,832





    9,002





    0.15



    Litigation provision (c)





    (10,242)





    -





    10,242





    1.6 %





    -





    10,242





    2,458





    7,784





    0.13



    Restructuring costs and certain other items (d)





    (8,347)





    -





    8,347





    1.3 %





    -





    8,347





    2,055





    6,292





    0.11



    Retention bonus obligation (f)





    (5,725)





    (1,909)





    7,634





    1.2 %





    -





    7,634





    1,832





    5,802





    0.10

    Adjusted Non-GAAP



    $

    160,464



    $

    42,686



    $

    171,903





    27.0 %



    $

    2,259



    $

    152,913



    $

    21,837



    $

    131,076



    $

    2.21





























































    Three Months Ended April 1, 2023























































    GAAP



    $

    183,435



    $

    42,691



    $

    174,168





    25.4 %



    $

    1,388



    $

    165,173



    $

    24,250



    $

    140,923



    $

    2.38

    Adjustments:

























































    Purchased intangibles amortization (b)





    (1,479)





    -





    1,479





    0.2 %





    -





    1,479





    335





    1,144





    0.02



    Restructuring costs and certain other items (d)





    405





    -





    (405)





    (0.1 %)





    -





    (405)





    256





    (661)





    (0.01)



    Acquisition related costs (e)





    (8,342)





    -





    8,342





    1.2 %





    -





    8,342





    2,002





    6,340





    0.11

    Adjusted Non-GAAP



    $

    174,019



    $

    42,691



    $

    183,584





    26.8 %



    $

    1,388



    $

    174,589



    $

    26,843



    $

    147,746



    $

    2.49





























































    (a)

    Selling & administrative expenses include purchased intangibles amortization.

    (b)

    The purchased intangibles amortization, a non-cash expense, was excluded to be consistent with how management evaluates the performance of its core business against historical operating results and the operating results of competitors over periods of time.

    (c)

    Litigation provisions and settlement gains were excluded as these items are isolated, unpredictable and not expected to recur regularly.

    (d)

    Restructuring costs and certain other items were excluded as the Company believes that the cost to consolidate operations, reduce overhead, and certain other income or expense items are not normal and do not represent future ongoing business expenses of a specific function or geographic location of the Company.

    (e)

    Acquisition related costs include all incremental expenses incurred, such as advisory, legal, accounting, tax, valuation, and other professional fees. The Company believes that these costs are not normal and do not represent future ongoing business expenses.

    (f)

    In connection with the Wyatt acquisition, the Company started to recognize a two-year retention bonus obligation that is contingent upon the employee's providing future service and continued employment with Waters. The Company believes that these costs are not normal and do not represent future ongoing business expenses.

     

    Waters Corporation and Subsidiaries

    Preliminary Condensed Unclassified Consolidated Balance Sheets

    (In thousands and unaudited)



























































    March 30, 2024



    December 31, 2023

















    Cash, cash equivalents and investments





    $                338,213



    $                395,974

    Accounts receivable







    626,329



    702,168

    Inventories









    538,634



    516,236

    Property, plant and equipment, net





    633,594



    639,073

    Intangible assets, net







    611,147



    629,187

    Goodwill









    1,297,826



    1,305,446

    Other assets









    463,221



    438,770

       Total assets









    $             4,508,964



    $             4,626,854

































    Notes payable and debt







    $             2,055,761



    $             2,355,513

    Other liabilities









    1,196,678



    1,121,000

       Total liabilities







    3,252,439



    3,476,513

















    Total stockholders' equity







    1,256,525



    1,150,341

       Total liabilities and stockholders' equity





    $             4,508,964



    $             4,626,854

     

    Waters Corporation and Subsidiaries

    Preliminary Condensed Consolidated Statements of Cash Flows

    Three Months Ended March 30, 2024 and April 1, 2023

    (In thousands and unaudited)























    Three Months Ended









    March 30, 2024



    April 1, 2023











    Cash flows from operating activities:









    Net income

    $                     102,196



    $                   140,923



    Adjustments to reconcile net income to net













    cash provided by operating activities:











    Stock-based compensation

    10,913



    12,805





    Depreciation and amortization

    48,514



    31,154





    Change in operating assets and liabilities and other, net

    101,247



    11,869







    Net cash provided by operating activities

    262,870



    196,751















    Cash flows from investing activities:









    Additions to property, plant, equipment













    and software capitalization

    (28,655)



    (34,390)



    Investments in unaffiliated companies

    (1,064)



    -



    Net change in investments

    (25)



    (16)







    Net cash used in investing activities

    (29,744)



    (34,406)















    Cash flows from financing activities:









    Net change in debt

    (300,000)



    (94,960)



    Proceeds from stock plans

    13,932



    2,378



    Purchases of treasury shares

    (13,089)



    (69,505)



    Other cash flow from financing activities, net

    6,981



    2,876







    Net cash used in financing activities

    (292,176)



    (159,211)















    Effect of exchange rate changes on cash and cash equivalents

    1,264



    2,407







    (Decrease) increase in cash and cash equivalents

    (57,786)



    5,541















    Cash and cash equivalents at beginning of period

    395,076



    480,529







    Cash and cash equivalents at end of period

    $                     337,290



    $                   486,070

























































    Reconciliation of GAAP Cash Flows from Operating Activities to Free Cash Flow (a)











































    Net cash provided by operating activities - GAAP

    $                     262,870



    $                   196,751

















    Adjustments:











    Additions to property, plant, equipment













    and software capitalization

    (28,655)



    (34,390)





    Litigation settlements received, net

    (375)



    (375)





    Major facility renovations

    -



    4,466

    Free Cash Flow - Adjusted Non-GAAP

    $                     233,840



    $                   166,452





























    (a)

    The Company defines free cash flow as net cash flow from operations accounted for under GAAP less capital expenditures and software capitalizations plus or minus any unusual and non recurring items. Free cash flow is not a GAAP measurement and may not be comparable to free cash flow reported by other companies.

     























    Waters Corporation and Subsidiaries

    Reconciliation of Projected GAAP to Adjusted Non-GAAP Financial Outlook



















































    Three Months Ended



    Twelve Months Ended









    June 29, 2024



    December 31, 2024











    Range







    Range





    Projected Sales









































    Organic constant currency sales growth rate (a)

    (6.0 %)

    -

    (4.0 %)



    (0.5 %)

    -

    1.5 %



    Impact of:





















    Currency translation

    (2.0 %)

    -

    (2.0 %)



    (0.6 %)

    -

    (0.6 %)





    Acquisitions



    1.5 %

    -

    1.5 %



    1.1 %

    -

    1.1 %



    Sales growth rate as reported

    (6.5 %)

    -

    (4.5 %)



    0.0 %

    -

    2.0 %























































    Range







    Range





    Projected Earnings Per Diluted Share







































    GAAP earnings per diluted share

    $      2.28

    -

    $      2.38



    $    10.90

    -

    $    11.20



    Adjustments:





















    Purchased intangibles amortization

    $      0.15

    -

    $      0.15



    $      0.60

    -

    $      0.60





    Retention bonus obligation

    $      0.07

    -

    $      0.07



    $      0.25

    -

    $      0.25



    Adjusted non-GAAP earnings per diluted share

    $      2.50

    -

    $      2.60



    $    11.75

    -

    $    12.05















































    (a) Organic constant currency growth rates are a non-GAAP financial measure that measures the change in net sales between current and prior year periods, excluding the impact of foreign currency exchange rates during the current period and excluding the impact of acquisitions made within twelve months of the acquisition close date. These amounts are estimated at the current foreign currency exchange rates and based on the forecasted geographical sales in local currency, as well as an assessment of market conditions as of today, and may differ significantly from actual results.

























    These forward-looking adjustment estimates do not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance.







    Contact: Caspar Tudor, Head of Investor Relations – (508) 482-2429

    Cision View original content:https://www.prnewswire.com/news-releases/waters-corporation-nyse-wat-reports-first-quarter-2024-financial-results-302137145.html

    SOURCE Waters Corporation

    Get the next $WAT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WAT

    DatePrice TargetRatingAnalyst
    3/31/2025$460.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/26/2025$396.00 → $407.00Neutral → Outperform
    Robert W. Baird
    2/13/2025$450.00Sector Perform → Sector Outperform
    Scotiabank
    2/10/2025$360.00 → $415.00Underweight → Equal Weight
    Barclays
    1/10/2025$430.00Mkt Perform → Outperform
    Bernstein
    12/23/2024Sector Perform
    Scotiabank
    10/8/2024$355.00 → $415.00Hold → Buy
    Jefferies
    8/28/2024$380.00Overweight
    Wells Fargo
    More analyst ratings

    $WAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Fearon Richard H bought $332,900 worth of shares (1,000 units at $332.90), increasing direct ownership by 153% to 1,653 units (SEC Form 4)

      4 - WATERS CORP /DE/ (0001000697) (Issuer)

      5/29/24 11:23:35 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Waters Corporation to Present at the Jefferies Global Healthcare Conference

      MILFORD, Mass., May 16, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4th, 2025, at 8:45AM Eastern Time. A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will be available for 90 days. About Waters Corporation Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences f

      5/16/25 11:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Integrates Multi-Angle Light Scattering Detectors with Empower Software for Improved Biologics Quality Control and Simplified Regulatory Compliance

      News Summary  Saves up to six months on compliant software validation in biopharmaceutical quality control.1Reduces analysis time for biotherapeutic peptides and proteins by 20%.2Enhances quality control by providing absolute molecular weight of biologics and avoiding common errors encountered with other techniques.3MILFORD, Mass., May 6, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that its Empower™ Software now supports biologics data acquisition and quality control (QC) analysis from Multi-Angle Light Scattering (MALS) and differential Refractive Index (RI) instruments in its Wyatt Technology™ Portfolio. This integration expands the scope of critical quality attribut

      5/6/25 6:15:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Corporation (NYSE: WAT) Reports First Quarter 2025 Financial Results

      Highlights Strong start to the year as first quarter 2025 sales of $662 million landed at the high-end of guidance range; grew 4% as reported and 7% in constant currencyResults led by instrument growth of 11% in constant currency, driven by strong momentum in Pharma and Industrial end marketsEarnings landed at the high-end of guidance range with GAAP EPS of $2.03 and non-GAAP EPS of $2.25Raising full-year constant currency sales growth guidance to +5.0% to +7.0%, given first quarter strengthRaising full-year non-GAAP EPS guidance to the range of $12.75 to $13.05, net of tariff impact, operational actions, and improvement in FXFirst Quarter 2025 MILFORD, Mass., May 6, 2025 /PRNewswire/ -- Wat

      5/6/25 6:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Waters upgraded by KeyBanc Capital Markets with a new price target

      KeyBanc Capital Markets upgraded Waters from Sector Weight to Overweight and set a new price target of $460.00

      3/31/25 7:57:55 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded Waters from Neutral to Outperform and set a new price target of $407.00 from $396.00 previously

      3/26/25 7:47:54 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters upgraded by Scotiabank with a new price target

      Scotiabank upgraded Waters from Sector Perform to Sector Outperform and set a new price target of $450.00

      2/13/25 8:14:37 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Leadership Updates

    Live Leadership Updates

    See more
    • Waters Corporation Appoints Heather Knight to Board of Directors

      MILFORD, Mass., Aug. 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International. Heather is an accomplished leader who brings decades of experience across the pharma and medical device industries."Heather is an accomplished leader who brings decades of experience across the pharmaceutical and medical device industries, with a proven track record for

      8/14/24 4:15:00 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Corporation Appoints Richard Fearon to Board of Directors

      Waters™ Corporation (NYSE:WAT) today announced the appointment of Richard Fearon to its Board of Directors, effective March 27, 2023. Mr. Fearon is the former Vice Chairman and Chief Financial and Planning Officer of Eaton Corporation, a multinational power management company. "Rick's expertise is at the intersection of financial excellence, strategic development and transformation, which are the key pillars of Waters' growth plan. We are confident that Rick's unique skillset will complement our Board well and we look forward to benefiting from his insights as we continue to drive value for shareholders," said Dr. Flemming Ornskov, Chairman of the Board. Dr. Udit Batra, CEO and President,

      3/28/23 8:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Corporation Appoints Dan Brennan and Mark Vergnano to Board of Directors

      Waters Corporation (NYSE:WAT) today announced the appointment of Dan Brennan and Mark Vergnano, to its Board of Directors, effective November 23, 2022. Mr. Brennan currently serves as Executive Vice President and Chief Financial Officer of Boston Scientific Corporation, a global medical device company, and Mr. Vergnano is the former Chairman, President and Chief Executive Officer of The Chemours Company, a chemistry company. "Dan and Mark are outstanding leaders whose decades of experience in the medical device and chemistry industries will add tremendous value as Waters continues to execute its exciting growth strategy," said Dr. Flemming Ornskov, Chairman of the Board. "These appointment

      11/23/22 8:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Waters Corporation

      SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

      11/12/24 11:54:03 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Waters Corporation (Amendment)

      SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

      2/14/24 9:37:22 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Waters Corporation (Amendment)

      SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

      2/13/24 5:17:31 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Financials

    Live finance-specific insights

    See more
    • Waters Corporation (NYSE: WAT) Reports First Quarter 2025 Financial Results

      Highlights Strong start to the year as first quarter 2025 sales of $662 million landed at the high-end of guidance range; grew 4% as reported and 7% in constant currencyResults led by instrument growth of 11% in constant currency, driven by strong momentum in Pharma and Industrial end marketsEarnings landed at the high-end of guidance range with GAAP EPS of $2.03 and non-GAAP EPS of $2.25Raising full-year constant currency sales growth guidance to +5.0% to +7.0%, given first quarter strengthRaising full-year non-GAAP EPS guidance to the range of $12.75 to $13.05, net of tariff impact, operational actions, and improvement in FXFirst Quarter 2025 MILFORD, Mass., May 6, 2025 /PRNewswire/ -- Wat

      5/6/25 6:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • Waters Corporation Schedules First Quarter 2025 Earnings Conference Call

      MILFORD, Mass., April 8, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q1 2025 financial results conference call on Tuesday, May 6th, 2025 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least June 3rd, 2025, at midnight Eastern Time. About Waters Corporation  Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food

      4/8/25 4:30:00 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    SEC Filings

    See more
    • SEC Form 10-Q filed by Waters Corporation

      10-Q - WATERS CORP /DE/ (0001000697) (Filer)

      5/6/25 7:00:36 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Corporation filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - WATERS CORP /DE/ (0001000697) (Filer)

      5/6/25 6:05:51 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEFA14A filed by Waters Corporation

      DEFA14A - WATERS CORP /DE/ (0001000697) (Filer)

      4/9/25 4:16:58 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP & Chief Financial Officer Chaubal Amol covered exercise/tax liability with 239 shares, decreasing direct ownership by 4% to 5,224 units (SEC Form 4)

      4 - WATERS CORP /DE/ (0001000697) (Issuer)

      5/14/25 5:22:52 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SVP TA Instruments Division Bennett Jianqing covered exercise/tax liability with 303 shares, decreasing direct ownership by 6% to 4,916 units (SEC Form 4)

      4 - WATERS CORP /DE/ (0001000697) (Issuer)

      4/8/25 5:43:17 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Jiang Wei was granted 53 shares, increasing direct ownership by 2% to 2,410 units (SEC Form 4)

      4 - WATERS CORP /DE/ (0001000697) (Issuer)

      4/2/25 5:12:56 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials